AMG National Trust Bank boosted its holdings in shares of Exelon Co. (NASDAQ:EXC – Get Rating) by 4.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,525 shares of the company’s stock after acquiring an additional 350 shares during the quarter. AMG National Trust Bank’s holdings in Exelon were worth $282,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the business. WESTERN FINANCIAL Corp grew its holdings in Exelon by 20.5% during the 3rd quarter. WESTERN FINANCIAL Corp now owns 22,544 shares of the company’s stock worth $845,000 after acquiring an additional 3,841 shares during the last quarter. Ieq Capital LLC boosted its stake in shares of Exelon by 12.5% in the 3rd quarter. Ieq Capital LLC now owns 21,215 shares of the company’s stock valued at $795,000 after purchasing an additional 2,351 shares during the last quarter. First Republic Investment Management Inc. boosted its stake in shares of Exelon by 10.4% in the 3rd quarter. First Republic Investment Management Inc. now owns 511,206 shares of the company’s stock valued at $19,150,000 after purchasing an additional 48,152 shares during the last quarter. Citizens Business Bank bought a new stake in shares of Exelon in the 3rd quarter valued at $375,000. Finally, Eudaimonia Partners LLC boosted its stake in shares of Exelon by 101.6% in the 3rd quarter. Eudaimonia Partners LLC now owns 28,407 shares of the company’s stock valued at $1,064,000 after purchasing an additional 14,313 shares during the last quarter. 80.60% of the stock is owned by institutional investors.
Exelon Trading Down 0.7 %
EXC opened at $41.51 on Wednesday. The company has a debt-to-equity ratio of 1.45, a quick ratio of 0.72 and a current ratio of 0.81. The business’s fifty day simple moving average is $41.90. Exelon Co. has a 1-year low of $35.19 and a 1-year high of $50.71. The firm has a market capitalization of $41.25 billion, a P/E ratio of 19.22, a price-to-earnings-growth ratio of 2.67 and a beta of 0.60.
Exelon Cuts Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th were given a dividend of $0.3375 per share. The ex-dividend date was Monday, November 14th. This represents a $1.35 annualized dividend and a dividend yield of 3.25%. Exelon’s dividend payout ratio is currently 62.50%.
Wall Street Analyst Weigh In
EXC has been the topic of a number of analyst reports. Seaport Res Ptn reaffirmed a “buy” rating on shares of Exelon in a research note on Monday, October 24th. BMO Capital Markets cut their target price on shares of Exelon from $51.00 to $41.00 in a research note on Tuesday, October 18th. Guggenheim cut their target price on shares of Exelon from $49.00 to $40.00 in a research note on Monday, October 24th. Wells Fargo & Company increased their target price on shares of Exelon to $47.00 in a research note on Wednesday, December 14th. Finally, Credit Suisse Group increased their target price on shares of Exelon from $42.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Exelon presently has a consensus rating of “Moderate Buy” and an average target price of $46.00.
Exelon Company Profile
Exelon Corp. operates as a utility services holding company, which engages in the energy generation, power marketing, and energy delivery business. It operates through the following segments: Mid Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT) and other Power Regions. The Mid-Atlantic segment represents operations in the eastern half of PJM, which includes New Jersey, Maryland, Virginia, West Virginia, Delaware, the District of Columbia and parts of Pennsylvania and North Carolina.
- Get a free copy of the StockNews.com research report on Exelon (EXC)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Exelon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelon and related companies with MarketBeat.com's FREE daily email newsletter.